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S U M M A R Y
Background: Although there has been substantial progress in controlling pertussis in South Korea, the
reported number of pertussis case-patients has gradually been increasing during the last decade. To
address this, we summarized the surveillance data on pertussis collected during the period 1955–2011.
Detailed epidemiologic and clinical data were determined, primarily using data from recent years.
Methods: We analyzed data from the national surveillance system to describe the occurrence of
pertussis. The annual numbers of reported pertussis case-patients were identiﬁed for the period 1955–
2000. For 2001–2009, information including limited demographic characteristics and the date of onset of
symptoms were identiﬁed. For 2010–2011, detailed epidemiologic and clinical information of reported
pertussis case-patients were collected.
Results: During 1955–2011, the secular trend was characterized by a gradual decrease in the reported
number of cases from 1955 to the late 1990s, then a recent increase starting in the early 2000s. In 2009, a
large number of reported cases occurred in infants <1 year of age. In 2011, an increase in reported cases
among adolescents and adults aged 15 years was observed. During 2010–2011, 29.8% of reported cases
were not immunized and 11.3% had not been immunized in a timely manner. Of adolescents and adults
aged 15 years, 91.7% did not have a record of immunization.
Conclusions: During 2010–2011, a shift in age group was observed in pertussis case-patients: 33.8% were
young infants <3 months of age and 29.0% were adolescents and adults 15 years of age. Considering
that infants without timely vaccination may be vulnerable to an increased risk of pertussis infection,
steps to provide timely vaccination to infants, to provide Tdap vaccination to adolescents and adults, and
to enhance surveillance to capture adult pertussis cases should be taken in South Korea.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. 
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Pertussis is a highly communicable disease caused by the
bacterium Bordetella pertussis, characterized by paroxysmal cough
including inspiratory whoop and post-tussive vomiting.1 Prior to
the introduction of a vaccine, pertussis was common in infants and
young children and sometimes caused severe complications such
as pneumonia, seizures, encephalopathy, and death.2 During the
past decades, the availability of pertussis vaccine in combination
with diphtheria and tetanus toxoids has markedly decreased the
incidence of pertussis to a low level.3 Yet, pertussis continues to
produce a substantial childhood disease burden in countries with
incompletely implemented vaccination programs.4* Corresponding author. Tel.: +82 43 719 7348; fax: +82 43 719 7379.
E-mail address: choeyj@yahoo.com (D.-h. Lee).
1201-9712   2012 International Society for Infectious Diseases. Published by Elsevie
http://dx.doi.org/10.1016/j.ijid.2012.07.012Despite achieving high vaccination coverage, some countries
have reported an increase in pertussis incidence in recent years.5–7
The lack of natural booster events and waning immunity in
adolescents and adults have been implicated in this resurgence of
pertussis.8,9 Furthermore, the resurgence could possibly be
attributed to an increase in pertussis among young infants
resulting from the reduced transfer of transplacental antibody
from mother to fetus.10
In South Korea, the government started to recommend routine
DTwP (diphtheria, tetanus, and whole cell pertussis) vaccination in
1954 and introduced the DTaP (diphtheria, tetanus, and acellular
pertussis) vaccine into the National Immunization Program (NIP)
in 1989, and there has since been substantial progress in
controlling pertussis, with low numbers of reported cases until
the 2000s.11,12 However, the reported number of pertussis case-
patients has gradually been increasing during the last decade.13 To
date, the factors affecting this increase in pertussis in South Korea
remain unclear.r Ltd. Open access under the Elsevier OA license.
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targeting infants and children less than 7 years of age may be
implicated in the recent increase in pertussis in South Korea.14 In
2009, the Tdap vaccine (reduced dose tetanus, diphtheria, and
pertussis) was licensed in South Korea for use in adolescents and
adults aged older than 11 years.15 However, additional data from
multiple years are needed to guide decisions on the adoption of
the Tdap vaccination into the NIP. To address this, we
summarized the surveillance data on pertussis collected in
South Korea during 1955 to 2011 with a view to identifying the
susceptible population and to provide baseline data for the
pertussis prevention and control policy in South Korea. Detailed
epidemiologic and clinical data were determined primarily using
data from recent years.
2. Methods
2.1. National surveillance
The national pertussis surveillance system was ﬁrst established
in 1954 in South Korea.12 It involves the passive reporting of
clinically diagnosed case-patients by medical practitioners. In
2001, a major revision was made to the system, resulting in the
collection of data using the standardized clinical and laboratory
case deﬁnition of pertussis based on the World Health Organiza-
tion (WHO) case deﬁnition, and active investigation of passively
reported case-patients.16 In 2010, the Korea Centers for Disease
Control and Prevention (KCDC) updated the pertussis case
surveillance system to collect complete and detailed information,
including route of transmission and disease severity for all
reported case-patients.
2.2. Pertussis immunization program
Although pertussis vaccination has been recommended for
universal vaccination for the past 50 years, data on national
vaccination coverage are very limited in South Korea. The recent
estimated vaccination coverage for the full series (at least four
doses) of DTaP vaccine in children ranged between 65.7% and
94.0%.13,17
2.3. Data collection and analysis
We analyzed data for the period 1955–2011 collected by the
national surveillance system to describe the occurrence of
pertussis in South Korea. From 1955 to 2000, only the annual
numbers of reported pertussis case-patients were identiﬁed. From
2001 to 2009, information including limited demographic
characteristics and date of the onset of symptoms were identiﬁed.
From 2010 to 2011, detailed epidemiologic and clinical informa-
tion of reported pertussis case-patients were collected. For case-
patients reported in 2010–2011, we used the case deﬁnition as
described by the WHO: a clinical case is deﬁned as a case diagnosed
as pertussis by a physician, or a person with a cough lasting at least
2 weeks with at least one of the following symptoms: paroxysm of
coughing, inspiratory whooping, or post-tussive vomiting. Labo-
ratory conﬁrmation is deﬁned as isolation of B. pertussis, or
detection of genomic sequences by means of PCR from a clinical
pertussis case-patient.16
Note that the analysis of epidemiologic and clinical information
was considered only for the 2010–2011 surveillance data because
data for 1955–2009 were incomplete (most of the clinical and
demographic information were missing). Because we used data
from a legally mandated, government-sponsored routine surveil-
lance system, institutional review board approval and informed
consent were not required for the KCDC.3. Results
3.1. Secular trends 1955–2011
From 1955 to 2011, a total of 178,265 pertussis case-patients
were passively reported in South Korea (Figure 1). Four major
peaks were observed before the 1990s: 33 218 cases in 1961–1962,
8373 cases in 1966, 8592 cases in 1969–1970, and 3176 cases in
1980–1981. The secular trend was characterized by a gradual
decrease in reported numbers from 1955 to the late 1990s, then a
gradual increase starting in the early 2000s (Figure 2).
During 2001–2011, the number of reported pertussis case-
patients was highest among infants <1 year of age. In 2009, a large
number of reported cases occurred in infants <1 year of age
(n = 58). There was, however, an increase in reported cases among
adolescents and adults aged 15 years in 2011 (n = 34; Figure 2).
During 2001–2003 and 2004–2006, pertussis case-patients
were reported throughout the year, with increases observed
during the summer season between July and August, peaking
during October and November (Figure 3). During 2007–2009 and
2010–2011, the increase in reported cases occurred earlier than in
the previous years: the increase was observed during the late
spring season in May, peaking during August and September.
During 2010–2011, there was another peak observed in November.
3.2. Epidemiologic and clinical ﬁndings 2010–2011
The frequencies and percentages of pertussis case-patients
reported in 2010–2011 by selected epidemiologic characteristics
are shown in Table 1. Among 124 case-patients, 95 (76.6%) were
conﬁrmed by laboratory methods. Among 42 infants aged <3
months, 42.9% had their symptom onset during October–
December, whereas 44.1% of adolescents and adults aged 15
years had symptom onset earlier, during July–September. Of 124
pertussis case-patients, 24.2% were found to have identiﬁed the
source of transmission as another family member. A total of 14
(11.3%) pertussis case-patients were found not to have been
immunized in a timely manner. Among 24 infants aged 3–11
months, six (25%) did not receive vaccination in a timely manner.
Of adolescents and adults aged 15 years, 97.7% did not have a
record of immunization.
The frequencies and percentages of selected clinical character-
istics in pertussis case-patients reported in 2010–2011 are shown
in Table 2. Overall, 69.4% (86/124) of pertussis case-patients had a
paroxysmal cough, whereas 9.7% (12/124) had only mild
symptoms such as mild cough and/or rhinorrhea. Of infants aged
<3 months, 64.3% (27/42) had inspiratory whoop, whereas only
13.9% (5/36) of adolescents and adults aged 15 years had this
symptom. Of infants aged <3 months, 45.2% (19/42) had apnea
and/or dyspnea, whereas 16.7% (6/36) of adolescents and adults
had this symptom. Nineteen of 42 infants aged <3 months (45.2%)
were hospitalized, and 10 (23.8%) had respiratory complications
such as pneumonia or bronchiolitis.
4. Discussion
This is the ﬁrst published report of national pertussis
surveillance data for South Korea covering a period of 56 years.
As the data for 1955–2000 were not collected using a standardized
case deﬁnition for suspected pertussis infection, we focused on the
2001–2009 and 2010–2011 periods, for which more complete and
detailed data on case-patients were available.
Although pertussis has traditionally been a disease affecting
young children, observations on the age group distribution depict a
shift in the age group of pertussis case-patients in South Korea.
During 2010–2011, 33.8% (42/124) of pertussis case-patients were
Figure 1. Number of pertussis case-patients reported nationally in South Korea, 1955–2011.
Figure 3. Reported number of pertussis case-patients for years 2001–2003, 2004–2006, 2007–2009, and 2010–2011, by month of symptom onset, South Korea.
Figure 2. Age-group distribution and total number of pertussis case-patients, by reporting year, South Korea, 2001–2011.
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from elsewhere for other countries that have reported a resurgence
of pertussis even though they have achieved high vaccination
coverage.7,18 Moreover, our observation of the high proportion of
pertussis case-patients in adolescents and adults aged 15 years
(29.0%, 36/124) is in consonance with other reports that have
pointed towards an age shift in pertussis incidence to an older
susceptible population.19,20 This shift in pertussis infection in
adolescents and adults may lead to serious consequences for
susceptible infants, because adolescents (usually older siblings)
and adults (parents or grandparents) are the potential sources of
infection for young infants less than 3 months of age.21
Recent surveillance data for pertussis from other countries have
shown an upward and/or downward shift in age distribution. In
countries with a high quality pertussis vaccination program suchas Taiwan, Switzerland, and Germany, many cases have been seen
in infants <1 year of age; however, adolescents and the adult age
group have also accounted for an increased proportion of cases.22–
24 The reasons for this change may include the increased level of
surveillance over more recent years, the decrease in vaccine-
induced or natural booster-induced population immunity, and a
demographic transition or shift.25,26
In this study, we also found that timely vaccination was not
received in 11.3% (14/124) of the case-patients, and vaccination
history was not documented in 91.7% (33/36) of the adolescents
and adults aged over 15 years. Strengthening of routine DTaP
vaccination should be the cornerstone of pertussis control and it
could be achieved by providing timely vaccination to infants and
children coupled with providing sustainable outreach services. In
2012, 253 public health centers and >6000 private clinics
Table 1

















Laboratory conﬁrmed cases 31 (73.8) 15 (83.3) 5 (83.3) 10 (83.3) 5 (71.4) 2 (66.7) 27 (75) 95 (76.6)
Male sex 24 (57.1) 11 (61.1) 2 (33.3) 3 (25) 5 (71.4) 0 (0) 13 (36.1) 58 (46.8)
Month of symptom onset
Jan–Mar 11 (26.2) 3 (17.6) 2 (40) 1 (9.1) 1 (16.7) 0 (0) 1 (2.9) 19 (15.3)
Apr–Jun 8 (19.0) 5 (29.4) 1 (20) 3 (27.3) 1 (16.7) 3 (100) 7 (20.6) 28 (22.6)
Jul–Sep 5 (11.9) 7 (41.2) 1 (20) 5 (45.5) 0 (0) 0 (0) 15 (44.1) 33 (26.6)
Oct–Dec 18 (42.9) 2 (11.8) 1 (20) 2 (18.2) 4 (66.7) 0 (0) 11 (32.4) 38 (30.6)
Unknown 0 1 1 1 1 0 2 6 (4.8)
Intrafamilial transmissiona 17 (40.5) 4 (22.2) 1 (16.7) 3 (25) 0 (0) 1 (33.3) 4 (11.1) 30 (24.2)
Living with infant <12 months - - - 5 (41.7) 2 (28.6) 1 (33.3) 8 (22.2) 16 (12.9)
Vaccination status
0 dose 34 (81.0) 3 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 37 (29.8)
1 dose 8 (19.0) 14 (77.8) 0 (0) 0 (0) 1 (14.3) 0 (0) 0 (0) 23 (18.5)
2 doses - 1 (5.6) 2 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 3 (2.4)
3 doses - - 4 (66.7) 3 (25) 1 (14.3) 0 (0) 0 (0) 8 (6.5)
4 doses - - - 7 (58.3) 2 (28.6) 0 (0) 0 (0) 9 (7.3)
5 doses - - - 1 (8.3) 2 (28.6) 2 (66.7) 2 (5.6) 7 (5.6)
Non-timely vaccinationb - 4 (22.2) 2 (33.3) 4 (33.3) 4 (57.1) 0 (0) - 14 (11.3)
Unknown vaccination history - - - 1 (8.3) 1 (14.3) 1 (33.3) 33 (91.7) 36 (29.0)
a Refers to two or more family members who live at the same postal address and are reported as pertussis case-patients.
b Refers to pertussis case-patients who had not completed DTaP vaccination 1 dose by 2 months; 2 doses by 4 months; 3 doses by 6 months; 4 doses by 18 months;
and 5 doses by 6 years of age.
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Paroxysmal cough 31 (73.8) 13 (72.2) 3 (50) 7 (58.3) 5 (71.4) 1 (33.3) 26 (72.2) 86 (69.4)
Inspiratory whoop 27 (64.3) 10 (55.6) 1 (16.7) 3 (25) 0 (0) 0 (0) 5 (13.9) 46 (37.1)
Post-tussive vomiting 9 (21.4) 6 (33.3) 2 (33.3) 0 (0) 1 (14.3) 0 (0) 3 (8.3) 21 (16.9)
Apnea and/or dyspnea 19 (45.2) 7 (38.9) 2 (33.3) 1 (8.3) 0 (0) 0 (0) 6 (16.7) 35 (28.2)
Cyanosis 15 (35.7) 5 (27.8) 2 (33.3) 1 (8.3) 0 (0) 0 (0) 2 (5.6) 25 (20.2)
Mild cough and/or rhinorrhea, only 1 (2.4) 1 (5.6) 1 (16.7) 3 (25) 2 (28.6) 0 (0) 4 (11.1) 12 (9.7)
Reported complications
Pneumonia or bronchiolitis 10 (23.8) 5 (27.8) 1 (16.7) 1 (8.3) 1 (14.3) 1 (33.3) 2 (5.6) 21 (16.9)
Hospitalization 19 (45.2) 10 (55.6) 1 (16.7) 1 (8.3) 3 (42.9) 1 (33.3) 5 (13.9) 40 (32.3)
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registry system, which keeps electronic records of all vaccines
given at that institution. In order to improve timeliness and
completion of vaccination, the systems provide a free reminder/
recall notiﬁcation cellular-phone message to the parents.
Moreover, utilizing Tdap vaccination for adolescents and
adults to prevent transmission from the primary source of
infection to unprotected infants should be a public health priority.
In 2012, the Korean Advisory Committee on Immunization
Practices decided to introduce the Tdap vaccine into the NIP,
with the aim of providing protection against pertussis to
adolescents and adults who could be the potential source of
infection for infants who have not yet completed DTaP vaccina-
tion.27 Tdap is now recommended for adolescents aged 11–12
years who have completed their DTaP vaccination series;
adolescents and adults aged 11–64 years who have frequent
contact with infants <1 year of age; and for any wounded patients
who require Td (tetanus–diphtheria vaccine) vaccination – Tdap
may be given instead of Td.15 Since January 2012, full ﬁnancial
support for Tdap vaccination from the government has been
provided for adolescents aged 11–12 years.
Our ﬁndings demonstrate that although the majority (72.2%) of
adolescents and adults aged 15 years experienced paroxysmalcough, 11.1% had only minimal symptoms such as mild cough and/
or rhinorrhea. Similar to other studies that have demonstrated an
atypical presence of the typical clinical presentation for pertussis
in adults, our study revealed only 13.9%, 8.3%, and 16.7% of
adolescents and adults experienced inspiratory whoop, post-
tussive vomiting, and dyspnea, respectively.1,28 Since recent
studies have shown that adolescents and adults are a reservoir
for pertussis infection and serve as a source of transmission within
the family, strengthening surveillance on adolescents and adults
with atypical symptoms of pertussis should be highlighted.29 We
discovered that the source of infection for 40.5% (17/42) of infants
less than 3 months of age was identiﬁed as being another family
member. Considering that infants younger than 3 months of age
usually stay at home and have no interaction other than with their
family members, conducting a sensitive and timely investigation
on the asymptomatic or atypical symptomatic family members
should be a public health priority.30
Our study using surveillance data to describe the epidemiology
and to evaluate the disease burden of pertussis has several
limitations. First, there are weaknesses in the design of the
surveillance system resulting from the need to balance limited
resources and data quality. For example, surveillance only covered
passive reporting from physicians who suspected a pertussis
Y.J. Choe et al. / International Journal of Infectious Diseases 16 (2012) e850–e854e854case-patient during 1955–2000. Moreover, 2001–2009 surveil-
lance collected only limited information on reported case-patients.
Second, improving the diagnosis by obtaining respiratory s
pecimens is often too technically difﬁcult for most health care
facilities. Although the preferred methods for the laboratory
diagnosis of pertussis are culture and PCR, not all institutions are
capable of running these tests. In response, the KCDC has
established a laboratory surveillance system that provides culture
and PCR for suspected pertussis case-patients identiﬁed at most
health care facilities; however, the system is still limited in terms
of quantity. Third, the recent increase in reported cases in South
Korea between 2001 and 2011 may be due to the intensiﬁcation of
recognition and surveillance systems. The recent increase in
pertussis in other countries has probably attracted the attention of
the health care professionals.
Despite these limitations, our data indicate the possibility of
suboptimal protection against pertussis for infants <3 months of
age, infants and children without timely vaccination, and
adolescents and adults aged 15 years. Although we are facing
an evolution in the pertussis vaccination program, the risk of
endemic transmission and individual infection may remain, which
underlines the need for comprehensive national baseline data. In
addition, based on our data, the long-term strategy for implement-
ing a pertussis vaccination program in South Korea needs to be re-
examined and re-evaluated.
In conclusion, we report the pertussis surveillance data from
South Korea for the period 1955–2011. Our data show that the
most common age groups affected during 2010–2011 were those
aged <3 months and 15 years. Considering that infants without
timely vaccination are at increased risk of pertussis infection,
steps to provide timely vaccination to infants and to provide
Tdap vaccination to adolescents and adults is now being
discussed in South Korea. Moreover, enhanced surveillance to
capture adult pertussis case-patients with atypical symptoms
should be in place in order to prevent transmission to vulnerable
infants. Financial support for Tdap vaccination from the
government may lead to a decrease in the susceptible popula-
tion among adolescents and adults.
Conﬂict of interest: No conﬂict of interest exists.
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